Sign up for the Abwiz Bio Newsletter to get actionable advice and exclusive deals direct to your inbox.
Phospho-Lck (Tyr505) (A3) rabbit mAb
20 μL is enough antibody for at least 20 Western blots.
Customers Also Viewed
|Description||Lck is a member of the Src family of non-receptor tyrosine kinases and plays a major role in T cell activation. Lck activates many downstream signaling pathways including Akt/mTOR, SAPK/JNK, PLCγ1, and RAS/MAPK. Phosphorylation of Lck at Tyr394 in the catalytic domain at the ATP-binding site stabilizes the open and active form, while phosphorylation at Tyr505 in the C-terminal domain promotes the closed, inactive conformation. Multiple small-molecule drugs used to treat leukemia have been shown to target inhibition of Lck, including imatinib and dasatinib. Lck is thus a promising target for suppressing T-cell responses for the treatment of inflammatory diseases or after organ transplantation.|
|Applications||Flow Cytometry, WB|
|Cross Reactivity||Predicted to work with mouse, rat and other homologues.|
|Immunogen||A synthetic phospho-peptide corresponding to residues surrounding Tyr505 of human phospho Lck|
|Formulation||1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA|
|Recommended Usage||1µg/mL – 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.|
|Pseudonyms||Tyrosine-protein kinase Lck, Leukocyte C-terminal Src kinase, LSK, Protein YT16, T cell-specific protein-tyrosine kinase|
|References||Serafin V, Capuzzo G, Milani G, et al. (2017) Blood. 130: 2750-2761.
Lee KC, Ouwehand I, Giannini AL, et al. (2010) Leukemia. 24: 896-900.
Flow cytometric analysis of Daudi cells secondary antibody only negative control (blue) or untreated (red) or treated with IFNα + IL-4 + pervanadate (green) using Phospho-Lck (Tyr505) antibody LckY505-A3 at 1 µg/mL. Cat. #2301.
Western blot analysis of Jurkat cell extract untreated or treated with 200nM calyculin A for 30min using Phospho-Lck (Tyr505) antibody LckY505-A3 at 0.1 µg/mL. Cat. #2301.
Peptide blocking flow cytometric analysis of Daudi cells secondary antibody only negative control (light blue) or untreated (red) or treated with IFNα + IL-4 + pervanadate (green) or untreated and blocked with phospho-peptide (black) or treated and blocked with phospho peptide (gold) or untreated and blocked with non-phospho peptide (dark blue) or treated and blocked with non-phospho peptide (purple) using Phospho-Lck (Tyr505) antibody LckY505-A3 at 1 µg/mL. Cat. #2301.
Western blot analysis of Jurkat cell extract, untreated or treated with calyculin A using 0.1 µg/mL Phospho-Lck (Tyr505) antibody LckY505-A3 Cat. #2301 or Company C antibody at 1 µg/mL (manufacturer’s recommended concentration) developed using the same exposure.
Phospho-Lck (Tyr505) (A3) rabbit mAb APC conjugateCatalog#: 2304
Phospho-Lck (Tyr505) (A3) rabbit mAb PE conjugateCatalog#: 2302
Phospho-Lck (Tyr505) (A3) rabbit mAb SureLight®488 conjugateCatalog#: 2305